Gene expression of glucocorticoid receptor alpha and beta in giant cell tumour of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Molecular and Cellular Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11476953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

  2000cited by this paper
• The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

  2000cited by this paper
• Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand.

  2000cited by this paper
• New Developments in the Pathogenesis and Treatment of Steroid‐Induced Osteoporosis

  1999cited by this paper
• Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.

  1999cited by this paper
• Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

  1999cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone.

  1999cited by this paper
• Osteoclasts from human giant cell tumors of bone lack estrogen receptors.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNAs in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization.

  1998cited by this paper
• Gene expression of monocyte chemoattractant protein‐1 in giant cell tumors of bone osteoclastoma: Possible involvement in CD68+ macrophage‐like cell migration

  1998cited by this paper
• A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

  1998cited by this paper
• TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

  1998cited by this paper
• Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

  1998cited by this paper
• Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

  1997cited by this paper
• Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones.

  1997cited by this paper
• Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis.

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Absence of glucocorticoid receptor-beta in mice.

  1997cited by this paper
• Purification and characterization of fully functional human osteoclast precursors

  1996cited by this paper
• The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function.

  1996cited by this paper
• Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans.

  1995cited by this paper
• Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.

  1994cited by this paper
• New model for bone resorption study in vitro: Human osteoclast‐like cells from giant cell tumors of bone

  1994cited by this paper
• Detection of mRNA for carbonic anhydrase II in human osteoclast‐like cells by in situ hybridization

  1993cited by this paper
• Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats.

  1992cited by this paper
• Modulation of osteoclast differentiation.

  1992cited by this paper
• The genomic structure of the human glucocorticoid receptor.

  1991cited by this paper
• Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria

  1990cited by this paper
• Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones.

  1989cited by this paper
• The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

  1989cited by this paper
• Bone histomorphometry in glucocorticoid-induced osteoporosis.

  1989cited by this paper
• Human giant cell tumors of bone identification and characterization of cell types.

  1987cited by this paper
• An immunohistological study of giant‐cell tumour of bone: Evidence for an osteoclast origin of the giant cells

  1985cited by this paper

• Myosin Heavy Chain Myopathy and Immune-Mediated Muscular Disorders.

  2025cites this paper
• Medical mystery: Deposition of calcium oxalate and phosphate stones in soft tissues

  2022cites this paper
• Calciphylaxis-as a drug induced adverse event

  2019cites this paper
• Immune-Mediated Muscle Diseases of the Horse

  2018cites this paper
• A 71-Year-Old Female with Myocardial Infarction and Long-Standing Ulcers on the Thigh

  2017cites this paper
• Suspected systemic calcinosis and calciphylaxis in 5 horses.

  2010cites this paper
• Glucocorticoid-Induced Osteoporosis: A Review

  2010cites this paper
• Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed.

  2009cites this paper
• Management of glucocorticoids-induced osteoporosis: role of teriparatide

  2009cites this paper
• Calciphylaxis from nonuremic causes: a systematic review.

  2008cites this paper
• Sex‐Specific Association of the Glucocorticoid Receptor Gene With Extreme BMD

  2007cites this paper
• Calciphylaxis: natural history, risk factor analysis, and outcome.

  2007cites this paper
• Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.

  2006cites this paper
• Characterization of Circulating Human Osteoclast Progenitors: Development of In Vitro Resorption Assay

  2005cites this paper
• Nuclear receptor signaling in macrophages.

  2004cites this paper
• Aromatase expression in the human fetal osteoblastic cell line SV-HFO.

  2004cites this paper
• Influence of Glucocorticoids on Human Osteoclast Generation and Activity

  2004cites this paper
• Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.

  2003cites this paper
• Bone effects of glucocorticoid therapy.

  2002cites this paper
• Giant cell tumor of bone

  2002cites this paper